Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
There's no doubt that Roche is playing catchup in the category, one of a lengthening list of pharma companies that are hoping to hit on effective 'me-too' products that can make a dent in the substantial lead held by market leaders Novo Nordisk and Eli Lilly, which already have injectable GLP-1s for diabetes and obesity on the market
Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes
Participants in trials for semaglutide lost an average of 37 lbs with the 1 ml per week drug dosage
(Its worth noting that Medicare and Medicaid do not cover GLP-1s, so be prepared to pay out of pocket for these peptides if you dont qualify for coverage
The brand's own footer disclosures note that "user results reflect recent internal statistics from paid orders" and that "rates may vary based on pharmacy capacity, state regulations, and individual order details." That means the 100,000+ figure reflects paid orders placed, not clinical outcomes
US$ 29.59
US$ 22.46
US$ 20.30
US$ 23.06
US$ 22.13
US$ 28.22
US$ 20.85
US$ 25.39
US$ 20.03
US$ 23.01
US$ 29.48
